Last week, Pfizer announced that the FDA fast-tracked its investigational gene therapy candidate (PF-06939926) for Duchenne muscular dystrophy. This will help expedite the approval process in the US, and we hope it will also mean a faster submission to Health Canada.
Pfizer is currently conducting Phase I and II clinical trials and plan to start the Phase III program soon.
To learn more about the Phase III program and how to get involved, speak to your physician and visit clinicaltrials.gov. Please note: The trial is limited to boys aged 4-7 years.